Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
RAPT Therapeutics (RAPT)
NASDAQ:RAPT
Holding RAPT?
Track your performance easily
RAPT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.91 - $27.35
Previous Close$0.91
Volume338.00K
Average Volume (3M)539.51K
Market Cap
$31.81M
Enterprise Value-$60.97M
Total Cash (Recent Filing)$97.91M
Total Debt (Recent Filing)$5.12M
Price to Earnings (P/E)―
Beta2.25
Next Earnings
Mar 06, 2025EPS Estimate
-$0.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.78
Shares Outstanding34,958,253
10 Day Avg. Volume320,300
30 Day Avg. Volume539,513
Standard Deviation0.28
R-Squared0.00018
Alpha-0.00937
Financial Highlights & Ratios
Price to Book (P/B)0.33
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.55
Forecast
1Y Price Target
$2.67Price Target Upside193.41% Upside
Rating ConsensusHold
Number of Analyst Covering5
RAPT Therapeutics News
PremiumCompany Announcements
RAPT Therapeutics Reprices Underwater Employee Stock Options
PremiumCompany Announcements
RAPT Therapeutics Reports Improved Q3 2024 Results
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentBetter-than-expected tivumecernon clinical data either as monotherapy or in combination with Keytruda could be a positive factor.
Financial StabilityRAPT ended with $97.9mn in cash and cash equivalents, which management expects will provide operational runway into 2026.
Strategic PartnershipsRAPT continues to seek a strategic partnership for future development and commercialization of tivumecirnon in oncology.
Bears Say
Financial PerformanceTarget price for RAPT has been lowered significantly due to reduced confidence in the CCR4 program.
Market SentimentAnalysts do not see the value creating catalysts in the near term to drive fundamental value or shift negative sentiment on RAPT shares.
Regulatory ChallengesThe termination of the zelnecirnon program creates uncertainty regarding the value inflection points that may be attainable within the operational runway window.
---
Ownership Overview
1.89% Insiders
23.95% Mutual Funds
25.11% Other Institutional Investors
42.14% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RAPT FAQ
What was RAPT Therapeutics’s price range in the past 12 months?
RAPT Therapeutics lowest stock price was $0.91 and its highest was $27.35 in the past 12 months.
What is RAPT Therapeutics’s market cap?
Currently, no data Available
When is RAPT Therapeutics’s upcoming earnings report date?
RAPT Therapeutics’s upcoming earnings report date is Mar 06, 2025 which is in 75 days.
How were RAPT Therapeutics’s earnings last quarter?
RAPT Therapeutics released its earnings results on Nov 12, 2024. The company reported -$0.47 earnings per share for the quarter, beating the consensus estimate of -$0.58 by $0.11.
Is RAPT Therapeutics overvalued?
According to Wall Street analysts RAPT Therapeutics’s price is currently Undervalued.
Does RAPT Therapeutics pay dividends?
RAPT Therapeutics does not currently pay dividends.
What is RAPT Therapeutics’s EPS estimate?
RAPT Therapeutics’s EPS estimate is -$0.42.
How many shares outstanding does RAPT Therapeutics have?
RAPT Therapeutics has 34,958,252 shares outstanding.
What happened to RAPT Therapeutics’s price movement after its last earnings report?
RAPT Therapeutics reported an EPS of -$0.47 in its last earnings report, beating expectations of -$0.58. Following the earnings report the stock price went down -0.571%.
Which hedge fund is a major shareholder of RAPT Therapeutics?
Among the largest hedge funds holding RAPT Therapeutics’s share is Woodline Partners LP. It holds RAPT Therapeutics’s shares valued at 476K.
---
RAPT Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$2.67 (193.41% Upside)
$2.67 (193.41% Upside)
Blogger Sentiment
Bullish
RAPT Sentiment 66%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 522.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▼ 11.6%
Last 30 Days ▼ 11.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-95.13%
12-Months-Change
Fundamentals
Return on Equity
-80.13%
Trailing 12-Months
Asset Growth
-45.69%
Trailing 12-Months
Company Description
RAPT Therapeutics
Rapt Therapeutics, Inc. operates as a clinical stage immunology-based biopharmaceutical company. It focuses on discovering, developing and commercializing oral small molecule therapies for patients in oncology and inflammatory diseases.. The company was founded in 2015 and is headquartered in South San Francisco, CA.
---
RAPT Stock 12 Month Forecast
Average Price Target
$2.67
▲(193.41% Upside)
Technical Analysis
Best Analysts Covering RAPT
1 Year
1 Year Success Rate
3/9 ratings generated profit
1 Year Average Return
-25.51%
downgraded a sell rating last month
Copying Anupam Rama's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -25.51% per trade.
---